Skip to main content
Erschienen in: Aesthetic Plastic Surgery 1/2022

02.09.2021 | Original Article

Rate of Incidental Pathological Lesions ın Reduction Mammoplasty Specimens and Incidence of Invasive Breast Carcinoma Following Breast Reduction Operation

verfasst von: Döndü Nergiz, Dinç Süren, Arsenal Sezgin Alikanoğlu, Hülya Tosun Yıldırım, Zelal Akgündüz Altun, Asım Uslu

Erschienen in: Aesthetic Plastic Surgery | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Reduction mammoplasty (RM) is one of the most frequently performed surgical procedures. The incidental determination of significant pathologic lesions (SPL), that is precursor and malignant lesions, in RM specimens is rare. The aim of this study was to determine the frequency of SPL in RM specimens, to evaluate the relationship between SPL and clinicopathological factors, and to examine the incidence of invasive breast carcinoma forming in the remaining breast tissue during the postoperative follow-up period developing in patients after RM operation.

Material and Method

This retrospective study included 874 females who underwent RM operation between January 2012 and January 2021. Demographic, clinicopathological findings, and preoperative radiological findings were recorded. The patients were followed up after the RM operation in respect of the first occurrence of breast cancer.

Results

Invasive carcinoma was determined in 0.2% and SPL in 3.5% in RM. The probability of SPL determination was greater in patients aged ≥ 40 years and with ≥ 4 paraffin blocks (p=0.038, p=0.01, respectively). No statistically significant difference was found between patients with and without SPL in respect of radiological findings (p=0.35). The mean postoperative follow-up period was 53.6 months, and invasive carcinoma was diagnosed during follow-up in 0.2% of all patients (6.9% of the patients with SPL).

Conclusion

Age over 40 years and an increased number of sampled blocks were found to be factors increasing the possibility of the determination of precursor and malignant lesions in RM specimens. RM could decrease the risk of the development of breast cancer.

Level of Evidence IV

This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.​springer.​com/​00266.
Literatur
1.
Zurück zum Zitat Ambaye AB, Goodwin AJ, MacLennan SE, Naud S, Weaver DL (2017) Recommendations for pathologic evaluation of reduction mammoplasty specimens: a prospective study with systematic tissue sampling. Arch Pathol Lab Med 141:1523–1528CrossRef Ambaye AB, Goodwin AJ, MacLennan SE, Naud S, Weaver DL (2017) Recommendations for pathologic evaluation of reduction mammoplasty specimens: a prospective study with systematic tissue sampling. Arch Pathol Lab Med 141:1523–1528CrossRef
2.
Zurück zum Zitat Kerrigan CL, Collins ED, Striplin D, Kim HM, Wilkins E, Cunningham B et al (2001) The health burden of breast hypertrophy. Plast Reconstr Surg 108:1591–1599CrossRef Kerrigan CL, Collins ED, Striplin D, Kim HM, Wilkins E, Cunningham B et al (2001) The health burden of breast hypertrophy. Plast Reconstr Surg 108:1591–1599CrossRef
3.
Zurück zum Zitat Usón Junior PLS, Callegaro Filho D, Bugano DDG, Geyer FC, de Nigro Corpa MV, Gonçalves PDS et al (2018) Incidental findings in reduction mammoplasty specimens in patients with no prior history of breast cancer. an analysis of 783 specimens. Pathol Oncol Res 24:95–99CrossRef Usón Junior PLS, Callegaro Filho D, Bugano DDG, Geyer FC, de Nigro Corpa MV, Gonçalves PDS et al (2018) Incidental findings in reduction mammoplasty specimens in patients with no prior history of breast cancer. an analysis of 783 specimens. Pathol Oncol Res 24:95–99CrossRef
5.
Zurück zum Zitat Ishag MT, Bashinsky DY, Beliaeva IV, Niemann TH, Marsh WL Jr (2003) Pathologic findings in reduction mammaplasty specimens. Am J Clin Pathol 120:377–380CrossRef Ishag MT, Bashinsky DY, Beliaeva IV, Niemann TH, Marsh WL Jr (2003) Pathologic findings in reduction mammaplasty specimens. Am J Clin Pathol 120:377–380CrossRef
6.
Zurück zum Zitat WHO Classification of Tumours Editorial Board (2019) WHO classification of tumours—Breast tumours. International Agency for Research on Cancer WHO Classification of Tumours Editorial Board (2019) WHO classification of tumours—Breast tumours. International Agency for Research on Cancer
7.
Zurück zum Zitat Kuehlmann B, Vogl FD, Kempny T, Djedovic G, Huemer GM, Hüttinger P et al (2020) Occult pathologic findings in reduction mammaplasty in 5781 patients-an international multicenter study. J Clin Med 13(9):2223CrossRef Kuehlmann B, Vogl FD, Kempny T, Djedovic G, Huemer GM, Hüttinger P et al (2020) Occult pathologic findings in reduction mammaplasty in 5781 patients-an international multicenter study. J Clin Med 13(9):2223CrossRef
8.
Zurück zum Zitat Albayrak A, Mesci CG, Güler G (2015) Histopathological findings obtained from reduction mammoplasty specimens. Turk J Med Sci 45:1374–1379CrossRef Albayrak A, Mesci CG, Güler G (2015) Histopathological findings obtained from reduction mammoplasty specimens. Turk J Med Sci 45:1374–1379CrossRef
10.
Zurück zum Zitat Li Z, Fadare O, Hameed O, Zhao C, Desouki MM (2014) Incidental atypical proliferative lesions in reduction mammoplasty specimens in patients with a history of breast cancer. Hum Pathol 45:104–109CrossRef Li Z, Fadare O, Hameed O, Zhao C, Desouki MM (2014) Incidental atypical proliferative lesions in reduction mammoplasty specimens in patients with a history of breast cancer. Hum Pathol 45:104–109CrossRef
11.
Zurück zum Zitat Samdanci ET, Firat C, Cakir E, Ak M, Sayin S, Nurkabul Z (2011) The incidence of non-proliferative and precancerous lesions of reduction mammoplasty: evaluation of 273 cases. Eur Rev Med Pharmacol Sci 15:1207–1211PubMed Samdanci ET, Firat C, Cakir E, Ak M, Sayin S, Nurkabul Z (2011) The incidence of non-proliferative and precancerous lesions of reduction mammoplasty: evaluation of 273 cases. Eur Rev Med Pharmacol Sci 15:1207–1211PubMed
12.
Zurück zum Zitat Dotto J, Kluk M, Geramizadeh B, Tavassoli FA (2008) Frequency of clinically occult intraepithelial and invasive neoplasia in reduction mammoplasty specimens: a study of 516 cases. Int J Surg Pathol 16:25–30CrossRef Dotto J, Kluk M, Geramizadeh B, Tavassoli FA (2008) Frequency of clinically occult intraepithelial and invasive neoplasia in reduction mammoplasty specimens: a study of 516 cases. Int J Surg Pathol 16:25–30CrossRef
13.
Zurück zum Zitat Goodwin JT, Decroff C, Dauway E, Sybenga A, Mahabir RC (2013) The management of incidental findings of reduction mammoplasty specimens. Can J Plast Surg 21:226–228CrossRef Goodwin JT, Decroff C, Dauway E, Sybenga A, Mahabir RC (2013) The management of incidental findings of reduction mammoplasty specimens. Can J Plast Surg 21:226–228CrossRef
14.
Zurück zum Zitat Acevedo F, Armengol VD, Deng Z, Tang R, Coopey SB, Braun D et al (2019) Pathologic findings in reduction mammoplasty specimens: a surrogate for the population prevalence of breast cancer and high-risk lesions. Breast Cancer Res Treat 173:201–207CrossRef Acevedo F, Armengol VD, Deng Z, Tang R, Coopey SB, Braun D et al (2019) Pathologic findings in reduction mammoplasty specimens: a surrogate for the population prevalence of breast cancer and high-risk lesions. Breast Cancer Res Treat 173:201–207CrossRef
15.
Zurück zum Zitat Clark CJ, Whang S, Paige KT (2009) Incidence of precancerous lesions in breast reduction tissue: a pathologic review of 562 consecutive patients. Plast Reconstr Surg 124:1033–1039CrossRef Clark CJ, Whang S, Paige KT (2009) Incidence of precancerous lesions in breast reduction tissue: a pathologic review of 562 consecutive patients. Plast Reconstr Surg 124:1033–1039CrossRef
16.
Zurück zum Zitat Sears ED, Lu YT, Chung TT, Momoh AO, Chung KC (2019) Pathology evaluation of reduction mammaplasty specimens and subsequent diagnosis of malignant breast disease: a claims-based analysis. World J Surg 43:1546–1553CrossRef Sears ED, Lu YT, Chung TT, Momoh AO, Chung KC (2019) Pathology evaluation of reduction mammaplasty specimens and subsequent diagnosis of malignant breast disease: a claims-based analysis. World J Surg 43:1546–1553CrossRef
17.
Zurück zum Zitat Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD et al (2007) American cancer society breast cancer advisory group. American cancer society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57(2):75–89CrossRef Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD et al (2007) American cancer society breast cancer advisory group. American cancer society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57(2):75–89CrossRef
18.
Zurück zum Zitat Merkkola-von Schantz PA, Kauhanen SMC, Jahkola TA, Krogerus LA, Hukkinen KS (2017) Breast cancer detection by preoperative imaging in reduction mammaplasty patients: a single center study of 918 patients. World J Surg 41(8):2013–2019CrossRef Merkkola-von Schantz PA, Kauhanen SMC, Jahkola TA, Krogerus LA, Hukkinen KS (2017) Breast cancer detection by preoperative imaging in reduction mammaplasty patients: a single center study of 918 patients. World J Surg 41(8):2013–2019CrossRef
19.
Zurück zum Zitat Berg WA, Zhang Z, Lehrer D, Jong RA, Pisano ED, Barr RG et al (2012) Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA 4307(13):1394–404 Berg WA, Zhang Z, Lehrer D, Jong RA, Pisano ED, Barr RG et al (2012) Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA 4307(13):1394–404
20.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424CrossRef Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424CrossRef
21.
Zurück zum Zitat Boice JD Jr, Friis S, McLaughlin JK, Mellemkjaer L, Blot WJ, Fraumeni JF Jr et al (1997) Cancer following breast reduction surgery in Denmark. Cancer Causes Control 8:253–258CrossRef Boice JD Jr, Friis S, McLaughlin JK, Mellemkjaer L, Blot WJ, Fraumeni JF Jr et al (1997) Cancer following breast reduction surgery in Denmark. Cancer Causes Control 8:253–258CrossRef
22.
Zurück zum Zitat Boice JD Jr, Persson I, Brinton LA, Hober M, McLaughlin JK, Blot WJ et al (2000) Breast cancer following breast reduction surgery in Sweden. Plast Reconstr Surg 106:755–762CrossRef Boice JD Jr, Persson I, Brinton LA, Hober M, McLaughlin JK, Blot WJ et al (2000) Breast cancer following breast reduction surgery in Sweden. Plast Reconstr Surg 106:755–762CrossRef
23.
Zurück zum Zitat Fryzek JP, Ye W, Nyrén O, Tarone RE, Lipworth L, McLaughlin JK (2006) A nationwide epidemiologic study of breast cancer incidence following breast reduction surgery in a large cohort of Swedish women. Breast Cancer Res Treat 97:131–134CrossRef Fryzek JP, Ye W, Nyrén O, Tarone RE, Lipworth L, McLaughlin JK (2006) A nationwide epidemiologic study of breast cancer incidence following breast reduction surgery in a large cohort of Swedish women. Breast Cancer Res Treat 97:131–134CrossRef
24.
Zurück zum Zitat Mastroianni M, Lin A, Hughes K, Colwell AS (2019) Proliferative lesions found at reduction mammaplasty: incidence and implications in 995 breast reductions. Plast Reconstr Surg 143:271e–275eCrossRef Mastroianni M, Lin A, Hughes K, Colwell AS (2019) Proliferative lesions found at reduction mammaplasty: incidence and implications in 995 breast reductions. Plast Reconstr Surg 143:271e–275eCrossRef
25.
Zurück zum Zitat Brinton LA, Persson I, Boice JD Jr, McLaughlin JK, Fraumeni JF Jr (2001) Breast cancer risk in relation to amount of tissue removed during breast reduction operations in Sweden. Cancer 91:478–483CrossRef Brinton LA, Persson I, Boice JD Jr, McLaughlin JK, Fraumeni JF Jr (2001) Breast cancer risk in relation to amount of tissue removed during breast reduction operations in Sweden. Cancer 91:478–483CrossRef
26.
Zurück zum Zitat Bondeson L, Linell F, Ringberg A (1985) Breast reductions: what to do with all the tissue specimens? Histopathology 9:281–285CrossRef Bondeson L, Linell F, Ringberg A (1985) Breast reductions: what to do with all the tissue specimens? Histopathology 9:281–285CrossRef
27.
Zurück zum Zitat Genco IS, Steinberg J, Caraballo Bordon B, Tugertimur B, Dec W, Hajiyeva S (2020) The rate of incidental atypical and malignant breast lesions in reduction mammoplasty specimens. Histopathology 76:988–996CrossRef Genco IS, Steinberg J, Caraballo Bordon B, Tugertimur B, Dec W, Hajiyeva S (2020) The rate of incidental atypical and malignant breast lesions in reduction mammoplasty specimens. Histopathology 76:988–996CrossRef
28.
Zurück zum Zitat Ayhan S, Başterzi Y, Yavuzer R, Latifoğlu O, Cenetoğlu S, Atabay K et al (2002) Histologic profiles of breast reduction specimens. Aesthetic Plast Surg 26:203–205CrossRef Ayhan S, Başterzi Y, Yavuzer R, Latifoğlu O, Cenetoğlu S, Atabay K et al (2002) Histologic profiles of breast reduction specimens. Aesthetic Plast Surg 26:203–205CrossRef
Metadaten
Titel
Rate of Incidental Pathological Lesions ın Reduction Mammoplasty Specimens and Incidence of Invasive Breast Carcinoma Following Breast Reduction Operation
verfasst von
Döndü Nergiz
Dinç Süren
Arsenal Sezgin Alikanoğlu
Hülya Tosun Yıldırım
Zelal Akgündüz Altun
Asım Uslu
Publikationsdatum
02.09.2021
Verlag
Springer US
Erschienen in
Aesthetic Plastic Surgery / Ausgabe 1/2022
Print ISSN: 0364-216X
Elektronische ISSN: 1432-5241
DOI
https://doi.org/10.1007/s00266-021-02558-z

Weitere Artikel der Ausgabe 1/2022

Aesthetic Plastic Surgery 1/2022 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.